Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Oncology is the branch of medicine that deals with the diagnosis and treatment of cancer. It includes medical oncology (the use of chemotherapy, hormone therapy, and other drugs to treat cancer), radiation oncology (the use of radiation therapy to treat cancer), and surgical oncology (the use of surgery and other procedures to treat cancer).
De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.
We profiled microglia using single-cell multi-omics techniques in lymphoma-bearing mice and patients who developed neurotoxicity after CAR19 T cell transfer. We discovered that microglial activation after CAR19 T cell infusion was mediated mainly by the kinase TAK1, which suggests that targeting TAK1 in patients receiving CAR19 T cell-based cancer immunotherapy could treat neurotoxicity.
In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.
De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.
We profiled microglia using single-cell multi-omics techniques in lymphoma-bearing mice and patients who developed neurotoxicity after CAR19 T cell transfer. We discovered that microglial activation after CAR19 T cell infusion was mediated mainly by the kinase TAK1, which suggests that targeting TAK1 in patients receiving CAR19 T cell-based cancer immunotherapy could treat neurotoxicity.
In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.
As quantum technology advances, it holds immense potential to accelerate oncology discovery through enhanced molecular modeling, genomic analysis, medical imaging, and quantum sensing.